Found: 17
Select item for more details and to access through your institution.
A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.
- Published in:
- EMBO Molecular Medicine, 2013, v. 5, n. 3, p. 353, doi. 10.1002/emmm.201201760
- By:
- Publication type:
- Article
Targeting of Deregulated Wnt/β-Catenin Signaling by PRI-724 and LGK974 Inhibitors in Germ Cell Tumor Cell Lines.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 8, p. 4263, doi. 10.3390/ijms22084263
- By:
- Publication type:
- Article
Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.
- Published in:
- International Journal of Molecular Sciences, 2017, v. 18, n. 8, p. 1660, doi. 10.3390/ijms18081660
- By:
- Publication type:
- Article
Differences Between Pediatric and Adult Protocols and Medical Centers in the Treatment of Acute Myeloid Leukemia in the United States.
- Published in:
- Journal of Adolescent & Young Adult Oncology, 2023, v. 12, n. 2, p. 147, doi. 10.1089/jayao.2021.0231
- By:
- Publication type:
- Article
Treatment of Acute Myeloid Leukemia in the Era of Genomics—Achievements and Persisting Challenges.
- Published in:
- Frontiers in Genetics, 2020, v. 11, p. 1, doi. 10.3389/fgene.2020.00480
- By:
- Publication type:
- Article
The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation.
- Published in:
- Therapeutic Advances in Hematology, 2023, v. 14, p. 1, doi. 10.1177/20406207231170708
- By:
- Publication type:
- Article
Pharmacological inhibition of Carbonic Anhydrase IX and XII to enhance targeting of acute myeloid leukaemia cells under hypoxic conditions.
- Published in:
- Journal of Cellular & Molecular Medicine, 2021, v. 25, n. 24, p. 11039, doi. 10.1111/jcmm.17027
- By:
- Publication type:
- Article
Engineering Tools for Regulating Hypoxia in Tumour Models.
- Published in:
- Journal of Cellular & Molecular Medicine, 2021, v. 25, n. 16, p. 7581, doi. 10.1111/jcmm.16759
- By:
- Publication type:
- Article
Classic and targeted anti‐leukaemic agents interfere with the cholesterol biogenesis metagene in acute myeloid leukaemia: Therapeutic implications.
- Published in:
- Journal of Cellular & Molecular Medicine, 2020, v. 24, n. 13, p. 7378, doi. 10.1111/jcmm.15339
- By:
- Publication type:
- Article
The rocky road to personalized medicine in acute myeloid leukaemia.
- Published in:
- Journal of Cellular & Molecular Medicine, 2018, v. 22, n. 3, p. 1411, doi. 10.1111/jcmm.13478
- By:
- Publication type:
- Article
Outcomes for Patients With Chronic Lymphocytic Leukemia (CLL) Previously Treated With Both a Covalent BTK and BCL2 Inhibitor in the United States: A Real-World Database Study.
- Published in:
- 2023
- By:
- Publication type:
- journal article
A multi‐institutional comparison of mitoxantrone, etoposide, and cytarabine vs high‐dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 8, p. 937, doi. 10.1002/ajh.25838
- By:
- Publication type:
- Article
The role of adjuvant chemotherapy in the management of acute promyelocytic leukemia differentiation syndrome.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.911745
- By:
- Publication type:
- Article
Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study.
- Published in:
- Advances in Hematology, 2022, p. 1, doi. 10.1155/2022/8262787
- By:
- Publication type:
- Article
Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy.
- Published in:
- EJHaem, 2024, v. 5, n. 5, p. 929, doi. 10.1002/jha2.1013
- By:
- Publication type:
- Article
Is Targeted Therapy Feasible in Acute Myelogenous Leukemia?
- Published in:
- Current Hematologic Malignancy Reports, 2014, v. 9, n. 2, p. 118, doi. 10.1007/s11899-014-0198-1
- By:
- Publication type:
- Article
Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling
- Published in:
- Molecular Oncology, 2012, v. 6, n. 3, p. 276, doi. 10.1016/j.molonc.2012.02.002
- By:
- Publication type:
- Article